Skip to main content

Table 1 Characteristics of Children with JIA and JIA-associated Uveitis

From: Characteristics of a cohort of children with Juvenile Idiopathic Arthritis and JIA-associated Uveitis

Characteristics

Group

Median (25th – 75th) unless otherwise specified

Overall (N = 287)

JIA (N = 235)

JIA-U (N = 52)

P-value

Demographics

    

 Gender, female, N (%)

205 (71.4 %)

165 (70.2 %)

40 (76.9 %)

0.332

 Hispanic, N (%)

24 (8.4 %)

16 (6.8 %)

8 (15.4 %)

0.043*

 Race, N (%)

    

  Caucasian

221 (77.0 %)

183 (77.9 %)

38 (73.1 %)

0.459

  African American

36 (12.5 %)

28 (11.9 %)

8 (15.4 %)

0.500

Other

30 (10.5 %)

24 (10.2 %)

6 (11.5 %)

0.800

Disease Characteristics

    

 Age JIA diagnosis (yrs.)

6.4 (2.9 – 11.7)

7.7 (3.8 – 12.0)

2.8 (1.8 – 6.6)

<0.001*

 Duration of JIA at last study visit (yrs.)

3.4 (1.8 – 5.9)

3.1 (1.6 – 5.3)

5.6 (2.9 – 8.9)

<0.001*

 Total follow up time (months, mean ± SD)

15.1 ± 12

14.2 ± 11.7

18.8 ± 12.7

0.012*

 JIA subtype, N (%)

    

  Oligo persistent

119 (41.1 %)

80 (34.0 %)

39 (75.0 %)

< 0.001*

  Oligo extended

14 (4.9 %)

12 (5.1 %)

2 (3.9 %)

0.754

  Polyarticular RF (−)

70 (24.4 %)

63 (26.8 %)

7 (13.5 %)

0.049*

  Polyarticular RF (+)

13 (4.5 %)

13 (5.5 %)

0 (0.0 %)

0.135

  Systemic

22 (7.7 %)

22 (9.4 %)

0 (0.0 %)

0.038*

  Psoriatic

10 (3.5 %)

10 (4.3 %)

0 (0.0 %

0.217

  Enthesitis related

37 (12.9 %)

33 (14.0 %)

4 (10.8 %)

0.260

  Undifferentiated

2 (0.7 %)

2 (0.9 %)

0 (0.0 %)

1.00

Labs, N (%) 1

    

 ANA (+) (n = 286)

112 (39.3 %)

84 (35.9 %)

28 (54.9 %)

0.017*

 RF (+) (n = 288)

26 (9.1 %)

26 (11.1 %)

0 (0.0 %)

0.013*

 Anti-CCP (+) (n = 285)

24 (8.5 %)

24 (10.3 %)

0 (0.0 %)

0.020*

 HLA-B27 (+) (n = 192)

32 (16.8 %)

26 (16.3 %)

6 (18.8 %)

0.740

 Earliest ESR (n = 283)

16 (6 – 38)

14.5 (6 – 38)

22 (8 – 38)

0.327

Medication Use, N (%) (n = 287)

    

 Methotrexate oral

160 (55.9 %)

124 (52.8 %)

36 (70.6 %)

0.020*

 Methotrexate injection

167 (58.4 %)

129 (54.9 %)

38 (74.5 %)

0.010*

 Infliximab

38 (13.3 %)

21 (8.9 %)

17 (33.3 %)

< 0.001*

 Etanercept

48 (17.0 %)

45 (19.4 %)

3 (5.9 %)

0.022*

 Adalimumab

64 (22.4 %)

52 (22.1 %)

12 (23.5 %)

0.828

 Abatacept

6 (2.1 %)

4 (1.7 %)

2 (3.9 %)

0.600

Quality of Life Scores (child) a

    

 PedsQLb Total

79.9 (66.5 – 90.2)

80.3 (66.5 – 90.2)

78.6 (66.2 – 90.7)

0.612

 PedsQLb Psychosocial

81.0 (67.2 – 90.3)

81.9 (69.4 – 90.5)

76.2 (65.0 – 89.7)

0.248

 CHAQc

0.25 (0.04 – 0.66)

0.25 (0.04 – 0.66)

0.25 (0.04 – 0.88)

0.690

 EYE-Qd

3.62 (3.38 – 3.82)

3.68 (3.46 – 3.84)

3.35 (2.88 - 3.56)

< 0.001*

Quality of Life Scores (parent) a

    

 PedsQLb Total

81.7 (66.3 – 90.7)

81.8 (65.6 – 89.7)

81.3 (69.2 – 92.5)

0.679

 PedsQLb Psychosocial

82.5 (67.9 – 92.5)

81.2 (68.1 – 92.3)

82.4 (67.1 – 92.6)

0.933

 CHAQc

0.25 (0.04 – 0.63)

0.31 (0.06 – 0.67)

0.15 (0 – 0.49)

0.091

 EYE-Qd

3.73 (3.48 – 3.86)

3.75 (3.55 – 3.88)

3.41 (3.20 – 3.64)

< 0.001*

  1. aIndicates missing data; *p = <0.05; bPediatric Quality of Life Inventory; cChildhood Health Assessment Questionnaire; dEffects of Youngsters Eyesight on Quality of Life
  2. Chi-square tests, two sample t-tests, non-parametric test (Mann Whitney-U or Kolmogorov-Smirnov test)
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096